A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Not yet recruiting · NCT07753824 · Registry updated 2026-08-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) | Neoplasms by Histologic Type, adenocarcinoma, appendix adenocarcinoma, carcinoma, cystic, mucinous, and serous neoplasm, epithelial neoplasm, mucinous adenocarcinoma, neoplasm | Not yet recruiting | Phase 2 | 2026-08-27 | NCT07753824 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cancer Prevention Research Institute of Texas | 29 |
| M.D. Anderson Cancer Center | 1145 |
| Summit Therapeutics | 31 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UT MD Anderson Cancer Center | Houston | United States | 204 |